Ben Franklin Healthcare Investments: 1.3 Million in Four Companies Ben Franklin Healthcare Investments continues support of SFA Therapeutics with additional investment….
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
Our microbiome-derived drugs are derived from natural substances and enable a new platform to develop treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients, providing safer treatments than current therapies.
Liver Diseases: Hepatitis B, Steatosis, NASH, NAFLD
Dermatology: Bullous Pemphigus (Rare Autoimmune Disease)
Ophthalmology: Uveitis
Oncology: Liver Cancer, Hepatocellular Carcinoma (HCC), Prevention of Cytokine Storm in CAR T Therapy.
Ben Franklin Healthcare Investments: 1.3 Million in Four Companies Ben Franklin Healthcare Investments continues support of SFA Therapeutics with additional investment….
SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition…
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results…
